D-beta-高丝氨酸 | 16504-57-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 丝氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: D-beta-高丝氨酸
• 中文别名: D-BETA-高丝氨酸
• 英文名称: (S)-3-amino-4-hydroxybutanoic acid
• 英文别名: (3S)-3-azaniumyl-4-hydroxybutanoate
• CAS: 16504-57-7
• 化学式: C₄H₉NO₃
• 分子量: 119.12
• InChiKey: BUZICZZQJDLXJN-VKHMYHEASA-N

物化性质

• 熔点：
  223-225 °C
• 沸点：
  374.5±32.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -4.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  83.6
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36
• 海关编码：
  2922509090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  D-beta-高丝氨酸 生成 (2S,6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-2-(hydroxymethyl)-8-(naphthalen-1- ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide
  参考文献：
  名称：

  TOPICAL AGENTS FOR DERMATOLOGICAL APPLICATIONS

  摘要：

  Provided are compounds of formula (I), (Ia), (Ib), and (Ic), and pharmaceutically and/or cosmeceutically acceptable salts thereof. Additionally provided are pharmaceutical and/or cosmeceutical compositions and formulations, comprising the compounds and/or salts thereof, therapeutic and/or cosmetic methods using same for modulating (e.g., inhibiting) CREB binding protein (CBP)/β-catenin mediated signaling in treating skin related diseases, conditions or disorders (e.g., dermatitis, psoriasis, scarring, alopecia, etc.) mediated by aberrant CBP/β-catenin signaling, and cosmetic methods for treating skin conditions (e.g., aging, etc.) mediated by aberrant CBP/β-catenin signaling.

  公开号：

  US20220106320A1
• 作为产物：
  描述：

  (E)-benzyl 4-hydroxybut-2-enoate 在 氨 、 lithium 、 sodium hydroxide 作用下， 以 四氢呋喃 、 叔丁醇 、 水 为溶剂， 反应 12.25h， 以51%的产率得到D-beta-高丝氨酸
  参考文献：
  名称：

  Homochiral oxazolidin-2-ones and imidazolidin-2-ones by tandem nucleophilic addition–conjugate addition

  摘要：

  Treatment of both primary alcohols 1a,b and secondary amines 1c,d, tethered to a Michael acceptor with (R)-phenylethyl isocyanate in the presence of DBU gave in good yield and high stereoselection diastereomeric mixtures of oxazolidin-2-ones 2a,b and 3a.b and imidazolidin-2-ones 2c,d and 3c,d, respectively. The cyclisation reaction Was Studied computationally by ab initio quantum mechanical methods. The observed stereoselectivity was explained on the basis of the different stability of both anions and transition states leading to 2a and 3a, respectively. The usefulness of the method was proven by conversion of 2a into the enantiomerically Pure bioactive amino acid 5. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2004.05.006

文献信息

• SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID-RELATED ORPHAN RECEPTOR
  申请人：Glaxo Group Limited

  公开号：US20140243362A1

  公开（公告）日：2014-08-28

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORγ wherein R 1 to R 7 are as defined in claim 35.

  本发明涉及一种新型的与视黄醇相关孤儿受体γ（RORγ）调节剂，其化学式为（I），以及用于制备这些调节剂的方法，含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症、代谢和自身免疫疾病中的应用，其中R1至R7如权利要求35所定义。
• [EN] SULFONAMIDE COMPOUNDS AND THEIR USE IN THE MODULATION RETINOID - RELATED ORPHAN RECEPTOR<br/>[FR] COMPOSÉS DE SULFONAMIDE ET LEUR UTILISATION DANS LA MODULATION DU RÉCEPTEUR ORPHELIN APPARENTÉ AU RÉCEPTEUR DES RÉTINOÏDES
  申请人：GLAXO GROUP LTD

  公开号：WO2013045431A1

  公开（公告）日：2013-04-04

  The present invention is directed to novel retinoid-related orphan receptor gamma (RORy) modulators of formula (I), processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammatory, metabolic and autoimmune diseases mediated by RORy wherein R1 to R7 are as defined in claim 1.

  本发明涉及一种新型的与视黄醇相关孤儿受体γ（RORγ）调节剂，其化学式为（I），以及制备这些调节剂的方法、含有这些调节剂的药物组合物，以及它们在治疗由RORγ介导的炎症性、代谢性和自身免疫性疾病中的应用，其中R1至R7如权利要求1所定义。
• Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)
  作者：Alexander M. Taylor、Alexandre Côté、Michael C. Hewitt、Richard Pastor、Yves Leblanc、Christopher G. Nasveschuk、F. Anthony Romero、Terry D. Crawford、Nico Cantone、Hariharan Jayaram、Jeremy Setser、Jeremy Murray、Maureen H. Beresini、Gladys de Leon Boenig、Zhongguo Chen、Andrew R. Conery、Richard T. Cummings、Leslie A. Dakin、E. Megan Flynn、Oscar W. Huang、Susan Kaufman、Patricia J. Keller、James R. Kiefer、Tommy Lai、Yingjie Li、Jiangpeng Liao、Wenfeng Liu、Henry Lu、Eneida Pardo、Vickie Tsui、Jian Wang、Yongyun Wang、Zhaowu Xu、Fen Yan、Dong Yu、Laura Zawadzke、Xiaoqin Zhu、Xiaoyu Zhu、Robert J. Sims、Andrea G. Cochran、Steve Bellon、James E. Audia、Steven Magnuson、Brian K. Albrecht

  DOI：10.1021/acsmedchemlett.6b00075

  日期：2016.5.12

  bromodomain-containing transcription coactivators involved in numerous cellular pathways relevant to oncology. As part of our effort to explore the potential therapeutic implications of selectively targeting bromodomains, we set out to identify a CBP/EP300 bromodomain inhibitor that was potent both in vitro and in cellular target engagement assays and was selective over the other members of the bromodomain family. Reported

  CBP 和 EP300 是高度同源的、含有溴结构域的转录共激活剂，参与与肿瘤学相关的许多细胞途径。作为探索选择性靶向布罗莫结构域潜在治疗意义的努力的一部分，我们着手鉴定一种 CBP/EP300 布罗莫结构域抑制剂，该抑制剂在体外和细胞靶标结合测定中均有效，并且比布罗莫结构域家族的其他成员具有选择性。这里报道了一系列 CBP/EP300 溴结构域的细胞有效和选择性探针，源自片段筛选命中 4-甲基-1,3,4,5-四氢-2H-苯并[b][1,4]地西平-2-一。
• An Approach to the Synthesis of anti-β²,³-Amino Acids: Application of β-Trifluoroacetamidoorganozinc Reagents
  作者：Richard Jackson、Hannah Bartrum

  DOI：10.1055/s-0029-1217721

  日期：2009.9

  An approach to the synthesis of ANTI-β 2 , 3 -aminoacids is reported. The key steps involve stereoselective lactonealkylation followed by ring opening with iodotrimethylsilane/ethanolto give iodo esters. Formation of the organozinc reagents from theseiodo esters, followed by either Pd- or Cu-catalysed reaction withelectrophiles gives protected β 2 -aminoacids is reported. The key steps involve stereoselective

  报道了一种合成 ANTI-β2, 3 -氨基酸的方法。关键步骤包括立体选择性内酯烷基化，然后用碘三甲基硅烷/乙醇开环得到碘酯。据报道，由这些碘酯形成有机锌试剂，然后通过 Pd 或 Cu 催化与亲电试剂反应，得到受保护的 β  2 - 氨基酸。关键步骤包括立体选择性内酯烷基化，然后用碘三甲基硅烷/乙醇开环得到碘酯。由这些碘酯形成有机锌试剂，然后通过 Pd 或 Cu 催化与亲电试剂反应，得到受保护的 β  2 , 3 -氨基酸。烯醇化物烷基化中的反式立体化学通过 X 射线晶体学证实了烯丙基化的抗内酯。
• Anticoagulant peptide alcohols
  申请人：Merrell Dow Pharmaceuticals

  公开号：US04971953A1

  公开（公告）日：1990-11-20

  This invention relates to peptide derivatives which are useful anticoagulant agents.

  这项发明涉及肽衍生物，它们是有用的抗凝剂。